Autologous stem-cell transplantation in multiple myeloma.
Autologous stem cell transplantation is an important option in the treatment of patients with multiple myeloma. 130 transplants using autologous marrow or peripheral stem cells were reported to the EBMT registry. The overall complete remission rate in evaluable patients was 48 percent. The median overall survival was 27 months. Factors of importance for survival were the response to treatment before transplantation, the stage at diagnosis, and the number of chemotherapy treatment lines before transplantation. Further studies should compare autologous bone marrow transplantation to chemotherapy and allogeneic transplantation.